Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Lexeo Therapeutics, Inc. ( (LXEO) ) has provided an update.
Lexeo Therapeutics reported fourth-quarter and full-year 2025 results on March 30, 2026, highlighting steady advancement of its cardiac gene therapy pipeline and a strengthened balance sheet. The company ended 2025 with $246.6 million in cash, cash equivalents and investments, supported by a $154 million equity raise in October 2025, and expects this to fund operations into 2028 despite a $100 million net loss for the year.
Operationally, Lexeo advanced LX2006 for Friedreich ataxia, with positive interim Phase I/II data through March 2026 showing sustained cardiac and neurologic benefits and a favorable safety profile, and secured FDA acceptance of an optimized Sf9 manufacturing process. The company submitted the SUNRISE-FA 2 pivotal trial protocol and statistical plan to the FDA in February 2026 and held a CMC readiness meeting in March 2026, keeping pivotal trial initiation and BLA-enabling activities on track.
For LX2020 in PKP2 arrhythmogenic cardiomyopathy, interim Phase I/II HEROIC PKP2 data reported in January 2026 and presented in March 2026 showed dose-dependent increases in PKP2 expression, reduced arrhythmia burden in high-dose cohorts and generally good tolerability, with further 12‑month high-dose data and FDA interactions planned in 2026. Lexeo also bolstered its cardiovascular leadership by appointing Narinder Bhalla as chief medical officer and entered a research collaboration with Johnson & Johnson to explore targeted cardiac delivery of AAV gene therapies, moves that enhance its late-stage and commercial readiness in the competitive cardiovascular genetic medicine space.
The most recent analyst rating on (LXEO) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Lexeo Therapeutics, Inc. stock, see the LXEO Stock Forecast page.
Spark’s Take on LXEO Stock
According to Spark, TipRanks’ AI Analyst, LXEO is a Neutral.
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and heavy ongoing cash burn) and bearish technical signals (below key moving averages with negative MACD). Valuation provides limited support given the negative P/E and lack of dividend data.
To see Spark’s full report on LXEO stock, click here.
More about Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. is a New York-based clinical-stage genetic medicine company focused on reshaping heart health through gene therapies for cardiovascular diseases. Its pipeline targets underlying genetic causes of conditions, including lead candidates LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for plakophilin-2 arrhythmogenic cardiomyopathy, alongside other programs in severe, high unmet-need indications.
Average Trading Volume: 998,403
Technical Sentiment Signal: Sell
Current Market Cap: $398.5M
Find detailed analytics on LXEO stock on TipRanks’ Stock Analysis page.